Eberhart 2009 Leukemia

From Bioblast
Revision as of 18:17, 31 January 2020 by Gnaiger Erich (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Publications in the MiPMap
Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis. Leukemia 23:2167-70.

» PMID: 19657369; Open Access

Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Leukemia

Abstract: Glucocorticoids (GCs) are an essential component of most chemotherapy protocols for lymphoid malignancies, particularly childhood acute lymphoblastic leukemia (ALL).1, 2 Nevertheless, adverse side effects of GCs call for improved therapy protocols.

GCs decrease the activity of glycolytic enzymes3 and upregulate the expression of the glycolytic regulator, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in vitro and in vivo.4 This led us to investigate whether co-administration of 2-deoxy-glucose (2-DG), an inhibitor of glycolysis, systemic application of which up to a blood concentration of approximately 3 mM had caused a transient hyperglycemia only,5 might potentiate the apoptotic effect of GC.


O2k-Network Lab: DE Regensburg Renner-Sattler K, DE Regensburg Renner-Sattler K


Labels: MiParea: Respiration  Pathology: Cancer 

Organism: Human  Tissue;cell: Blood cells, Lymphocyte  Preparation: Intact cells 


Coupling state: LEAK, ROUTINE, ET  Pathway: ROX  HRR: Oxygraph-2k 

Leukemia